Gsk Share Discussion Threads

[grupo guitarlumber] 26/6/2022 07:28

Drugs giant GSK says encouraging results from trial of its hepatitis B treatment raises hopes for millions suffering from chronic infection

By Neil Craven, Financial Mail on Sunday

Published: 21:50 BST, 25 June 2022 | Updated: 23:17 BST, 25 June 2022


Drugs giant GSK said encouraging results from a trial of its hepatitis B treatment have raised hopes for millions suffering from chronic infection.

It estimated its treatment bepirovirsen could generate peak annual sales of more than £2billion ($2.5billion) if later stage trials are successful.
Boost: GSK estimated its treatment bepirovirsen could generate peak annual sales of more than £2billion ($2.5billion) if later stage trials are successful

Boost: GSK estimated its treatment bepirovirsen could generate peak annual sales of more than £2billion ($2.5billion) if later stage trials are successful

The development follows positive news earlier this month from a phase three trial in older adults for its RSV vaccine for respiratory disease.

Shareholders including activist Elliott view the RSV vaccine, for which GSK will seek approval by the end of the year, as vital for the company's success and are likely to be cheered by the encouraging data on bepirovirsen.


How to choose the best (and cheapest) stocks and shares Isa and the right DIY investing platform

There are already effective vaccines for hepatitis B. But nearly 300 million people suffer long-lasting complications when the body is unable to fend off the virus.

Around 900,000 patients die each year from chronic hepatitis B and, even when treated, it can progress to complications including cirrhosis and liver cancer.

The pharmaceutical company said initial results from a mid-stage study raised hopes for what it called a 'functional cure'.

Chris Corsico, a senior vice president at the company, said yesterday the treatment has the potential to be 'transformative.'

GSK, whose chief executive Dame Emma Walmsley has been under attack by Elliott and other shareholders, is poised to spin off its Sensodyne toothpaste and Advil painkillers consumer healthcare business, Haleon, next month.

[jonjoneil] 25/6/2022 17:37

Unless they set a lowish price for Haleon at opening, I don't expect it to hold. Whereas I expect new GSK to open at a premium.

Question is, will the balance be positive?

[tradermichael] 25/6/2022 12:49

Destiny for Haleon ........?

[tradermichael] 25/6/2022 12:22

Well, one of the few multivalent boosters, I think - could be key to seeing off these newer Omicron strains and therefore an important milestone?

[patientcapital] 25/6/2022 09:47

Better late than never!

[tradermichael] 25/6/2022 08:14

I suppose this will be on the menu for the autumn vaccinations:

Sanofi SA said Friday that its coronavirus booster vaccine, developed alongside Britain's GSK PLC, has produced successful results against the Omicron variant of the coronavirus in an efficacy study.

The French biopharmaceutical company said its vaccine candidate showed efficacy against the virus in an environment of high Omicron variation. It showed 72% efficacy against the strain in adult, as well as a favorable safety and tolerability profile, the company said.

Along with positive data from two previous trials, the results will be submitted to regulatory authorities for approval, Sanofi said.

The results "indicate the potential of Sanofi-GSK's next-generation Beta-based booster to be a relevant response to public health needs," the company said.

[netcurtains] 24/6/2022 16:43

not at 16:32 - I think we can all work that one out.

[jonjoneil] 24/6/2022 16:32

No chance :-)

[netcurtains] 24/6/2022 11:02

Relx up 3%

[pierre oreilly] 24/6/2022 10:57

Yes.

But impossible to know what the chance is or how you'd work it out!

[netcurtains] 24/6/2022 10:46

any chance this will break 1800 today?

[johnrxx99] 24/6/2022 10:29

I bow to your superior knowledge.

[tradermichael] 24/6/2022 10:08

Burroughs Wellcome became Wellcome became Glaxo Wellcome became GlaxoSmithKline became GSK.

Splitting off from Burroughs Wellcome became Wellcome Trust, the most philanthropic of all..

[maywillow] 24/6/2022 08:03

Sanofi SA said Friday that its coronavirus booster vaccine, developed alongside Britain's GSK PLC, has produced successful results against the Omicron variant of the coronavirus in an efficacy study.

The French biopharmaceutical company said its vaccine candidate showed efficacy against the virus in an environment of high Omicron variation. It showed 72% efficacy against the strain in adult, as well as a favorable safety and tolerability profile, the company said.

Along with positive data from two previous trials, the results will be submitted to regulatory authorities for approval, Sanofi said.

The results "indicate the potential of Sanofi-GSK's next-generation Beta-based booster to be a relevant response to public health needs," the company said.



Write to Joshua Kirby at [e-mail]; @joshualeokirby



(END) Dow Jones Newswires

June 24, 2022 02:06 ET (06:06 GMT)

[johnrxx99] 24/6/2022 05:10

Welcome also.

[gibbs1] 23/6/2022 16:26

Michele Maatouk
Sharecast News
23 Jun, 2022 15:21 23 Jun, 2022 15:26


GlaxoSmithKline to invest £1bn in infectious disease R&D


GlaxoSmithKline said on Thursday it will invest £1bn over ten years to accelerate research and development (R&D) into infectious diseases that disproportionately impact lower-income countries.



The research will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases and anti-microbial resistance, which Glaxo said “continue to have a devastating toll on the most vulnerable, accounting for more than 60% of the disease burden in many lower-income countries".

Thomas Breuer, GSK’s chief global health officer, said: "I am delighted to renew our commitment to global health research for the coming decade, consistent with our purpose to unite our science, technology, and talent to get ahead of disease together and our ambition to deliver health impact at scale.

"Through our focus on scientific innovation in Global Health, we have delivered the first malaria vaccine, RTS,S, the first radical cure of vivax malaria, tafenoquine, and a new tuberculosis vaccine candidate."

He noted that the company now has more than 30 potential new vaccines and medicines - including pre-clinical assets - in 13 high-burden infectious diseases to accelerate.

[alphorn] 23/6/2022 14:21

Pfizer - eg. river blindness from memory.

[jonjoneil] 23/6/2022 14:14

Can't imagine Pfizer doing this.

[gateside] 23/6/2022 14:12

I think pharmaceutical companies often feel they have a philanthropic obligation to help mankind.I do agree it should probably be voted upon. And if so I'm sure it would pass easily.

[jonjoneil] 23/6/2022 13:58

TM
I totally agree. It's not their money.
Charitable donations should be kept separate from investments.

[tradermichael] 23/6/2022 12:49

I would have thought that this should be subject to a shareholder vote:


GSK PLC said Thursday that it will invest 1 billion pounds ($1.23 billion) to accelerate research and development over the next 10 years, targeting infectious diseases that disproportionately affect lower-income countries.

The British pharmaceutical company, formerly known as GlaxoSmithKline, said the investment will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV, neglected tropical diseases and anti-microbial resistance. These account for more than 60% of the disease burden in lower-income countries, the company said.

To deliver against its targets, GSK has formed a dedicated, non-commercial global health unit, measuring success by its effects on health alone without the concern of a commercial return on investment. This includes global health research and development hubs, which are advancing more than 30 potential new vaccines and medicines, targeting 13 high-burden infectious diseases.

[tradermichael] 21/6/2022 13:55

Seems to be a 'fashion' trend right now to split large global businesses, but this one is very strange:

Kellogg's has announced it's spinning off its cereal business as it plans to separate into three independent companies. It plans to separate into three independent public companies, sectioning off its iconic brands into distinct snacking, cereal and plant-based businesses.

The US food giant, which owns brands including Corn Flakes and Coco Pops, said the break-up will give each business a better chance to grow.

Steve Cahillane, chief executive of Kellogg, said: "These businesses all have significant standalone potential, and an enhanced focus will enable them to better direct their resources toward their distinct strategic priorities."

[tradermichael] 21/6/2022 13:50

It is, GSK intends to monetise its holding in Haleon in a disciplined manner to further strengthen the Company’s balance sheet.

[jonjoneil] 21/6/2022 13:33

Thanks TM.
I wonder why Glaxo couldn't have divested consumer in the same way?

[tradermichael] 21/6/2022 12:52

Prior to the Demerger, GlaxoSmithKline Consumer Healthcare Holdings (No. 2) Limited (“JVCo”), the current holding company of the Consumer Healthcare business, will pay dividends to GSK and Pfizer.

32 per cent. of HAL total ordinary ordinary share capital will be held by Pfizer. In keeping with Pfizer’s transformation into a more focused, global leader in science-based innovative medicines and vaccines, Pfizer intends to exit its 32 per cent. ownership interest in Haleon in a disciplined manner, with the objective of maximising value for Pfizer shareholders.